EOG and EMG: two important switches in automatic sleep stage classification

Sleep is a natural periodic state of rest for the body, in which the eyes are usually closed and consciousness is completely or partially lost. In this investigation we used the EOG and EMG signals acquired from 10 patients undergoing overnight polysomnography with their sleep stages determined by expert sleep specialists based on RK rules. Differentiation between Stage 1, Awake and REM stages challenged a well trained neural network classifier to distinguish between classes when only EEG-derived signal features were used. To meet this challenge and improve the classification rate, extra features extracted from EOG and EMG signals were fed to the classifier. In this study, two simple feature extraction algorithms were applied to EOG and EMG signals. The statistics of the results were calculated and displayed in an easy to visualize fashion to observe tendencies for each sleep stage. Inclusion of these features show a great promise to improve the classification rate towards the target rate of 100%

EEG feature extraction for classification of sleep stages

Automated sleep staging based on EEG signal analysis provides an important quantitative tool to assist neurologists and sleep specialists in the diagnosis and monitoring of sleep disorders as well as evaluation of treatment efficacy. A complete visual inspection of the EEG recordings acquired during nocturnal polysomnography is time consuming, expensive, and often subjective. Therefore, feature extraction is implemented as an essential preprocessing step to achieve significant data reduction and to determine informative measures for automatic sleep staging. However, the analysis of the EEG signal and extraction of sensitive measures from it has been a challenging task due to the complexity and variability of this signal. We present three different schemes to extract features from the EEG signal: relative spectral band energy, harmonic parameters, and Itakura distance. Spectral estimation is performed by using autoregressive (AR) modeling. We then compare the performance of these schemes with the view to select an optimal set of features for specific, sensitive, and accurate neuro-fuzzy classification of sleep stages.

Itakura Distance: A Useful Similarity Measure between EEG and EOG Signals in Computer-aided Classification of Sleep Stages

Sleep is a natural periodic state of rest for the body, in which the eyes usually close and consciousness is completely or partially lost. Consequently, there is a decrease in bodily movements and responsiveness to external stimuli. Slow wave sleep is of immense interest as it is the most restorative sleep stage during which the body recovers from weariness. During this sleep stage, electroencephalographic (EEG) and electro-oculographic (EOG) signals interfere with each other and they share a temporal similarity. In this investigation we used the EEG and EOG signals acquired from 10 patients undergoing overnight polysomnography with their sleep stages determined by certified sleep specialists based on RK rules. In this pilot study, we performed spectral estimation of EEG signals by Autoregressive (AR) modeling, and then used Itakura Distance to measure the degree of similarity between EEG and EOG signals. We finally calculated the statistics of the results and displayed them in an easy to visualize fashion to observe tendencies for each sleep stage. We found that Itakura Distance is the smallest for sleep stages 3 and 4. We intend to deploy this feature as an important element in automatic classification of sleep stages.

Kalman filter modeling of cerebral blood flow autoregulation

A parameter estimation scheme for dynamic systems is employed to simultaneously estimate the states and parameters of the model of human cerebral blood flow velocity as a function of mean arterial blood pressure. The estimation results show 20-40% reduction in the output mean square error compared to that of the one obtained from the computer model addressed in [1]. The estimation scheme estimates the parameters and states of the system, as well as the level of the observed and process noise variances. This approach is more extensive than the one that was applied to the same system in the previous work [2], in which only the Kalman filter was applied and the system was restricted to some specific constraints.

The use of R-wave morphology in the detection of sleep-disordered breathing using the electrocardiogram--a comparison between leads

Power spectral analysis of time series derived from the R-wave morphology of the ECG was employed to identify a suitable lead configuration for the detection of sleep-disordered breathing (SDB) using the electrocardiogram (ECG). 16 subjects (46 +/- 9.2 yrs, 8 males), who did not report problems during sleep, and 13 subjects previously diagnosed with SDB (49 +/- 8.8 yrs, 7 males) underwent an overnight sleep study at an accredited sleep center. Power values derived from the spectra of the R-peaks envelope were tested for their sensitivity and specificity in discriminating between epochs containing normal breathing from epochs containing SDB. Of the three tested lead configurations using two parameters NB1 and NB2 derived from the power spectrum, lead I produced the best results with a sensitivity of 92.8% and a specificity of 88.0% for the case of parameter NB1 and a sensitivity of 85.7% and a specificity of 76.0% for the case of parameter NB2.

Dynamic regulation of heart rate during acute hypotension: new insight into baroreflex function

To examine the dynamic properties of baroreflex function, we measured beat-to-beat changes in arterial blood pressure (ABP) and heart rate (HR) during acute hypotension induced by thigh cuff deflation in 10 healthy subjects under supine resting conditions and during progressive lower body negative pressure (LBNP). The quantitative, temporal relationship between ABP and HR was fitted by a second-order autoregressive (AR) model. The frequency response was evaluated by transfer function analysis.

RESULTS

HR changes during acute hypotension appear to be controlled by an ABP error signal between baseline and induced hypotension. The quantitative relationship between changes in ABP and HR is characterized by a second-order AR model with a pure time delay of 0.75 s containing low-pass filter properties. During LBNP, the change in HR/change in ABP during induced hypotension significantly decreased, as did the numerator coefficients of the AR model and transfer function gain.

CONCLUSIONS

1) Beat-to-beat HR responses to dynamic changes in ABP may be controlled by an error signal rather than directional changes in pressure, suggesting a "set point" mechanism in short-term ABP control. 2) The quantitative relationship between dynamic changes in ABP and HR can be described by a second-order AR model with a pure time delay. 3) The ability of the baroreflex to evoke a HR response to transient changes in pressure was reduced during LBNP, which was due primarily to a reduction of the static gain of the baroreflex.

A sleep laboratory evaluation of an automatic positive airway pressure system for treatment of obstructive sleep apnea

STUDY OBJECTIVES

This paper compares the performance of an experimental nasal positive airway pressure device that automatically adjusts the level of applied pressure (APAP) with the performance of a conventional continuous positive airway pressure (CPAP) in a sleep laboratory study.

DESIGN

In a randomized sequence, conventional CPAP therapy was applied for 1 night (CPAP night) and APAP therapy the following night (APAP night).

SETTING

The study was conducted in an accredited sleep disorders center.

PATIENTS OR PARTICIPANTS

Twenty-six men and 5 women between the ages of 35 to 73 (51 +/- 9.6) years with body mass index 35.82 +/- 8.35 (kg/m2) who were diagnosed (using standard nocturnal polysomnography [NPSG] methods) as having OSA syndrome were studied. The subjects were treated with conventional CPAP for approximately 8 (7.79 +/- 3.16) weeks at home prior to their participation in this study.

MEASUREMENTS AND RESULTS

All standard polysomnography data and nasal mask pressures were recorded using a computer-based data acquisition system. Sleep and respiratory data were scored by a registered polysomnographer. The mean apnea-hypopnea index (AHI) for subjects for the NPSG night was 55.2 +/- 33.7. It dropped to 4.2 +/- 3.8 for the CPAP night and to 5.4 +/- 5.4 for the APAP night. There was no significant (p = 0.05) difference between mean AHI indices, sleep stages, sleep stage shifts, and snore arousals for CPAP night and APAP night. However, all the measures showed significant (p = 0.05) improvement over NPSG night. The mean of APAP applied pressure (8.4 +/- 3.3 cm H2O) was significantly (p = 0.05) lower than the prescribed pressure (11.5 +/- 3.1 cm H2O), but there was no significant (p = 0.05) difference between the maximum APAP applied pressure (12.8 +/- 4.3 cm H2O) and the prescribed pressure (11.5 +/- 3.1 cm H2O). All mean comparison tests were carried out using two-tailed statistics.

CONCLUSIONS

APAP appears to be as effective as CPAP in treating OSA patients. APAP delivers the same level of therapy as CPAP, but it reduces the average airway pressure while providing needed peak pressures.

In vivo evaluation of a closed loop monitoring strategy for induced paralysis

OBJECTIVE

Reliable closed loop infusion systems for regulating paralysis level can be a great convenience to the anesthesiologists in automating their task. This paper describes the in vivo performance evaluation of a self-tuning controller that is designed to accommodate large variations in patient drug sensitivity, drug action delays and environmental interfering noise.

METHODS

The infusion system was evaluated in six adult mongrel dogs. Following the manual induction of paralysis by an anesthesiologist, the controller regulated the infusion of vecuronium to maintain a desired level of paralysis. The integrated EMG response of the hypothenar muscle to a train-of-four stimulation of the ulnar nerve quantified the depth of paralysis. The controller's robustness was tested by contaminating the sensed twitch signal with electrocautery noise and electrode disconnection.

RESULTS

The controller reached the initial level of paralysis of 100% in about 4.0 minutes and arrived at the desired level of 90% with an overshoot of 6.38% (+/-6.82). It maintained the desired level of paralysis with a 2.04% (+/-1.20) mean offset at 90% and 0.4% (+/-0.5) mean offset at 80% steady state level, respectively. The mean infusion rate to sustain 90% and 80% paralysis were 2.70 (+/-2.05) and 2.15 (+/-2.57) ((mg/kg)/min), respectively.

CONCLUSIONS

The system adapted to a large variation in the sample subject drug sensitivity. It remained stable despite large amplitude disturbances and maintained the paralysis at the desired level following the removal of the disturbances.

Candidate parasitic diseases

This paper discusses five parasitic diseases: American trypanosomiasis (Chagas disease), dracunculiasis, lymphatic filariasis, onchocerciasis and schistosomiasis. The available technology and health infrastructures in developing countries permit the eradication of dracunculiasis and the elimination of lymphatic filariasis due to Wuchereria bancrofti. Blindness due to onchocerciasis and transmission of this disease will be prevented in eleven West African countries; transmission of Chagas disease will be interrupted. A well-coordinated international effort is required to ensure that scarce resources are not wasted, efforts are not duplicated, and planned national programmes are well supported.

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries

Reported are the results of a study to determine the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in several developing countries where the disease is endemic (Brazil, India, and Kenya). At each study site, sequential cohorts of 10 patients each were treated with AmBisome at a dose of 2 mg.kg-1.day-1 (2 MKD). The first cohort received regimen 1:2 MKD on days 1-6 and day 10 (total dose: 14 mg/kg). If the efficacy with this regimen was satisfactory, a second cohort received regimen 2:2 MKD on days 1-4 and 10 (total dose: 10 mg/kg); and a third cohort received regimen 3:2 MKD on days 1, 5, and 10 (total dose: 6 mg/kg). In India, regimens 1, 2, and 3 (which were studied concurrently) each cured 100% of 10 patients. In Kenya, regimen 1 cured all 10 patients, regimen 2 cured 90% of 10 patients, but regimen 3 cured only 20% of 5 patients. In Brazil, regimen 1 was only partially curative: 5 of 13 patients (62%). Therefore, 15 patients were administered regimen 4 (2 MKD for 10 consecutive days; total dose, 20 mg/kg) and 13 patients were cured (83%). These results suggest that for the treatment of kala-azar the following doses of AmBisome should be administered: in India and Kenya, 2 mg/kg on days 1-4 and day 10; and in Brazil, 2 mg/kg on days 1-10.

A noninvasive technique for detecting obstructive and central sleep apnea

A new noninvasive method to detect obstructive and central sleep apnea [(OSA) and (CSA)] events is described. Data were collected from ten volunteer subjects with a previous diagnosis of OSA while they were titrated for continuous positive airway pressure (CPAP) therapy. Apneic events were identify by analyzing of estimated airway impedance determined from pressure and airflow signals delivered from CPAP. To enhance performance of this technique, a single-frequency (5 Hz with 0.5 cmH2O peak-to-peak amplitude) probing signal was superimposed on the applied CPAP pressure. The results indicated that estimated airway impedance during OSA (mean: 17.9, SD: 3.4, N = 50) was significantly higher then during CSA (mean: 4.1, SD: 1.7, N = 50). When the estimated impedance of OSA and CSA events were compared to a fixed threshold, 100% of all events can be correctly categorized. These results indicate that it may be possible to diagnose OSA and CSA noninvasively based upon this technique. The instrument and the algorithm required are relatively simple and can be incorporated in a home-based device. If this method was used for prescreening apnea patients, it could reduce cost, waiting time, and discomfort associated with traditional diagnostic procedures.

An artificial neural network-based controller for the control of induced paralysis using vecuronium bromide

This study presents an artificial neural network-based controller for regulating the level of induced paralysis during surgery using vecuronium bromide. The controller uses the myogram of a rapid muscle contractions (called twitch) to generate the appropriate infusion rate. The controller is self-adjusting and can accommodate inter- and intrapatient drug response variations. It also withstands changes in the pure time delay and nonlinear pharmacokinetic parameters of the response. Another feature of the controller is that it does not depend on a priori knowledge of the patient response model. Computer simulations using pharmacokinetic and pharmacodynamic models showed negligible steady-state error and maximum percent undershoot averaged to 6.24%. The average infusion rate for 90% paralysis was 1.22 (microg x kg(-1) x min[-1]).

Control of schistosomiasis — A global picture

The control of schistosomiasis has been a challenging task for most endemic countries. Thus, despite the concerted efforts to date, schistosomiasis remains a major public health concern, second only to malaria in the tropics and subtropics. In this review, Lorenzo Savioli and colleagues highlight changes in schistosomiasis prevalence and distribution over the past decades, discuss the success and limitations of the various control strategies, and present possible control initiatives for the future.

Pharyngeal wall vibration detection using an artificial neural network

An artificial-neural-network-based detector of pharyngeal wall vibration (PWV) is presented. PWV signals the imminent occurrence of obstructive sleep apnoea (OSA) in adults who suffer from OSA syndrome. Automated detection of PWV is very important in enhancing continuous positive airway pressure (CPAP) therapy by allowing automatic adjustment of the applied airway pressure by a procedure called automatic positive airway pressure (APAP) therapy. A network with 15 inputs, one output, and two hidden layers, each with two Adaline-nodes, is used as part of a PWV detection scheme. The network is initially trained using nasal mask pressure data from five positively diagnosed OSA patients. The performance of the ANN-based detector is evaluated using data from five different OSA patients. The results show that on the average it correctly detects the presence of PWV events at a rate of approximately 92% and correctly distinguishes normal breaths approximately 98% of the time. Further, the ANN-based detector accuracy is not affected by the pressure level required for therapy.

Strategies and tools for the control/elimination of lymphatic filariasis

Lymphatic filariasis infects 120 million people in 73 countries worldwide and continues to be a worsening problem, especially in Africa and the Indian subcontinent. Elephantiasis, lymphoedema, and genital pathology afflict 44 million men, women and children; another 76 million have parasites in their blood and hidden internal damage to their lymphatic and renal systems. In the past, tools and strategies for the control of the condition were inadequate, but over the last 10 years dramatic research advances have led to new understanding about the severity and impact of the disease, new diagnostic and monitoring tools, and, most importantly, new treatment tools and control strategies. The new strategy aims both at transmission control through community-wide (mass) treatment programmes and at disease control through individual patient management. Annual single-dose co-administration of two drugs (ivermectin + diethylcarbamazine (DEC) or albendazole) reduces blood microfilariae by 99% for a full year; even a single dose of one drug (ivermectin or DEC) administered annually can result in 90% reductions; field studies confirm that such reduction of microfilarial loads and prevalence can interrupt transmission. New approaches to disease control, based on preventing bacterial superinfection, can now halt or even reverse the lymphoedema and elephantiasis sequelae of filarial infection. Recognizing these remarkable technical advances, the successes of recent control programmes, and the biological factors favouring elimination of this infection, the Fiftieth World Health Assembly recently called on WHO and its Member States to establish as a priority the global elimination of lymphatic filariasis as a public health problem.

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

The efficacy and safety of 3 regimens of liposomal amphotericin B (AmBisome) in the treatment of Indian visceral leishmaniasis were compared in a prospective open randomized trial. Thirty parasitologically confirmed patients were randomly divided into 3 equal treatment groups; group 1 received AmBisome 2mg/kg on days 1, 2, 3, 4, 5, 6, and 10 (total dose 14 mg/kg); group 2 received AmBisome 2 mg/kg on days 1, 2, 3, 4, and 10 (total dose 10 mg/kg); group 3 received the same dosage on 1, 5 and 10 (total dose 6 mg/kg). Clinical cure resulted in all patients by day 24. Haemoglobin, white blood cell count, body weight and serum albumin level improved on day 24 and became normal by day 180. No patient relapsed within 12 months of follow-up. Side effects were minimal. One patient in group 2 died after 2 months from an unrelated disease. Liposomal amphotericin B is a promising new drug which is highly efficacious in the treatment of Indian kala-azar and produces minimal toxicity.

Automatic control of airway pressure for treatment of obstructive sleep apnea

Obstructive sleep apnea (OSA) occurs when airflow ceases because of pharyngeal wall collapse in sleep. Repeated apneic events results in the development of a pathological condition called OSA syndrome. We describe the methodology and design of a prosthetic device, named automatic positive airway pressure (APAP), for treatment of this syndrome. APAP applies a stream of air via a nasal mask at an initial pressure selected by the patient. By sensing specific pressure characteristics of air flow immediately preceding pharyngeal wall collapse, the APAP device automatically raises the applied pressure to maintain a patent upper airway and thus prevent apnea. Conversely, when such conditions are absent, pressure is lowered step wise until a preselected minimum pressure is reached. Performance evaluation of the APAP system in five OSA patients and five normal (asymptomatic for sleep apnea) subjects revealed that it effectively treated OSA syndrome. It lowered the apnea-hypopnea index without disturbing sleep and resulted in a lower mean airway pressure compared to the traditional continuous positive airway pressure (CPAP) therapy. The results also show that the pressure needed to prevent OSA varied significantly throughout the night. For OSA syndrome patients, this pressure ranged from 3 to 18 cm H2O. The mean airway pressure for these patients had a sample average of 6.80 cm H2O and a standard deviation of 3.17 cm H2O. In normal subjects, the device did not raise pressure except in response to Pharyngeal Wall Vibration events.

Accommodation of time delay variations in automatic infusion of sodium nitroprusside

A new self-tuning regulator for control of mean arterial blood pressure using sodium nitroprusside is presented. In addition to adapting to various patient response gains and time constants, the controller can accommodate variations in pure time delays, a problem that has not been addressed fully in previously proposed controllers. The control algorithm derivation is based on incorporating a self-tuning controller with an adaptive discrete time delay compensator. The derivation, however, is general and can potentially be applied to other pharmacological agents in addition to sodium nitroprusside. The a priori information required for implementation of the controller is the estimate of the order of the patient response transfer function and the range of the pure time delay. An attractive feature of the controller is its capability to optimize the level of the infused drug during the transient phase of the control without creating an output offset. This feature tends to reduce the overall level of the infused drug. Hence, it may be useful when the cost of a drug or its long-term administration side effects is of concern, such as in the case of sodium nitroprusside.

A controller for automatic regulation of induced paralysis during surgery

This paper presents a strategy for automatic control of induced paralysis using vecuronium bromide during surgery. The controller is self-tuning and adapts to inter-patient and intra-patient response variations while optimizing the output variance and infusion rate. In particular, the controller is capable of accommodating the variations of pure time delays in patient response. The performance of the controller is evaluated using an experimentally derived pharmacokinetic and nonlinear pharmacodynamic model of patient response. The results indicate that the controller provides robust regulation of the paralysis level with no output offset.

Analysis of the in vitro lymphoproliferative responses and antibody levels to the arc-5 antigen in patients with cystic hydatid disease

Using a commercially-available, purified, arc-5 antigen, we examined the in vitro proliferative responses of peripheral blood mononuclear cells from hydatid patients and from healthy controls. Antibody levels of different immunoglobulin classes were also measured against the same antigen, in sera of both groups. Our findings indicate that lymphocytes from healthy controls do not proliferate to the arc-5 antigen, whereas lymphocytes from the majority of patients do. The negative or weak responses observed among a few patients were not due either to increased release of prostaglandins in culture or to a lack of responsiveness to Interleukin-2. Antibodies of all three classes, G, M and A, measured by an ELISA, were elevated in sera of patients when compared with controls. However, only levels of specific IgG antibodies gave an excellent discrimination of the disease state and these were of diagnostic value. No direct or inverse correlations between lymphoproliferative responses and antibody levels were observed in either group, although a few patients with relatively low antibody titres demonstrated very high proliferative responses. The possible use of the proliferative assay as an adjunct to serology in the diagnosis of hydatid disease is indicated.

Antibody levels and in vitro lymphoproliferative responses to Streptococcus pyogenes erythrogenic toxin A and mitogen of patients with rheumatic fever

We investigated the in vitro lymphoproliferative responses to a streptococcal mitogen and erythrogenic toxin A of children with acute rheumatic fever (ARF) and patients with chronic rheumatic heart disease (CRHD). Antibody levels to the streptococcal products were also analyzed in the sera of those with ARF or chronic rheumatic heart disease as well as in the sera of children with streptococcal pharyngitis or poststreptococcal glomerulonephritis. Our results demonstrated that the individuals had depressed lymphoproliferative responses during the active stage of rheumatic fever. The depressed responses were not found either to be induced by time-sensitive mitogen-specific suppressor cells or to be related to a dose-response phenomenon. On the other hand, antibody levels to the extracellular mitogens were significantly elevated in the sera of children with ARF compared with the levels in the rest of the groups. The hyperresponsiveness noted among children with ARF was found to be at a quantitative level and was not due to recognition of more epitopes, as determined by Western blotting (immunoblotting). The profile of immune responsiveness in children with ARF to the streptococcal extracellular mitogens is discussed in relation to the pathogenesis of disease.